Comparison of expression profiles of metastatic versus primary mammary tumors in MMTV-Wnt-1 and MMTV-Nue transgenic mice

Neoplasia

Volumn 10, Issue 2, 2008, Pages 118-124

  Huang, Shixia ^a   Chen, Yidong ^b   Podsypanina, Katrina ^c   Li, Yi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; WNT1 PROTEIN;

ANIMAL CELL; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; LONG TERMINAL REPEAT; LUNG METASTASIS; METASTASIS; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MYOEPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 39049150399     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07637     Document Type: Article

References (53)

1. Allred DC, Brown P, and Medina D (2004). The origins of estrogen receptor alpha-positive and estrogen receptor-negative human breast cancer. Breast Cancer Res 6, 240-245.
2. Eccles SA and Welch DR (2007). Metastasis: recent discoveries and novel treatment strategies. Lancet 369, 1742-1757.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
4. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, and van't Veer LJ (2003). Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100, 15901-15905.
5. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, and van't Veer LJ (2005). Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65, 9155-9158.
6. Weigelt B, Wessels LF, Bosma AJ, Glas AM, Nuyten DS, He YD, Dai H, Peterse JL, and van't Veer LJ (2005). No common denominator for breast cancer lymph node metastasis. Br J Cancer 93, 924-932.
7. Weigelt B, Peterse JL, and van't Veer LJ (2005). Breast cancer metastasis: markers and models. Nat Rev Cancer 5, 591-602.
8. Chambers AF, Groom AC, and MacDonald IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572.
9. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, et al. (2002). Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 99, 6967-6972.
10. Crawford NP and Hunter KW (2006). New perspectives on hereditary influences in metastatic progression. Trends Genet 22, 555-561.
11. Van Dyke T and Jacks T (2002). Cancer modeling in the modern era: progress and challenges. Cell 108, 135-144.
12. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, and Muller WJ (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89, 10578-10582.
13. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, and Varmus HE (1988). Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55, 619-625.
14. Huang S, Li Y, Chen Y, Podsypanina K, Chamorro M, Olshen AB, Desai KV, Tann A, Petersen D, Green JE, et al. (2005). Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biol 6, R84.
15. Chen Y, Kamat V, Dougherty ER, Bittner ML, Meltzer PS, and Trent JM (2002). Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics 18, 1207-1215.
16. Li Y, Podsypanina K, Liu X, Crane A, Tan LK, Parsons R, and Varmus HE (2001). Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2, 2.
17. Kemler R, Brulet P, Schnebelen MT, Gaillard J, and Jacob F (1981). Reactivity of monoclonal antibodies against intermediate filament proteins during embryonic development. J Embryol Exp Morphol 64, 45-60.
18. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z, et al. (2003). Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100, 15853-15858.
19. Hynes NE and Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5, 341-354.
20. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
21. Munoz B and Bolander FF Jr (1989). Prolactin regulation of mouse mammary tumor virus (MMTV) expression in normal mouse mammary epithelium. Mol Cell Endocrinol 62, 23-29.
22. Gunther EJ, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB, and Chodosh LA (2002). A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 16, 283-292.
23. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, and Hennighausen L (2001). Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10, 545-553.
24. Clevers H (2006). Wnt/beta-catenin signaling in development and disease. Cell 127, 469-480.
25. Lindvall C, Bu W, Williams BO, and Li Y (2007). Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev 3, 157-168.
26. Liu BY, McDermott SP, Khwaja SS, and Alexander CM (2004). The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci USA 101, 4158-4163.
27. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, and Visvader JE (2006). Generation of a functional mammary gland from a single stem cell. Nature 439, 84-88.
28. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8, R76.
29. Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, and Li Y (2005). Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 24, 4220-4231.
30. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, and Cardiff RD (2002). Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 161, 1087-1097.
31. Cui XS and Donehower LA (2000). Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53. Oncogene 19, 5988-5996.
32. Yu Q, Geng Y, and Sicinski P (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021.
33. Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM, and Goodell MA (2002). Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol 245, 42-56.
34. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, and Eaves CJ (2006). Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997.
35. Brabletz T, Jung A, Spaderna S, Hlubek F, and Kirchner T (2005). Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5, 744-749.
36. Gangnus R, Langer S, Breit E, Pantel K, and Speicher MR (2004). Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 10, 3457-3464.
37. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, et al. (2004). HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101, 9393-9398.
38. Huang S, Podsypanina K, Chen Y, Cai W, Tsimelzon A, Hilsenbeck S, and Li Y (2006). Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat 5, 565-571.
39. Siegel PM, Dankort DL, Hardy WR, and Muller WJ (1994). Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14, 7068-7077.
40. Podsypanina K, Li Y, and Varmus H (2004). Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med 2, 24.
41. Jang JW, Boxer RB, and Chodosh LA (2006). Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol 26, 8109-8121.
42. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, and Weinberg RA (1999). Creation of human tumour cells with defined genetic elements. Nature 400, 464-468.
43. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, and Weinberg RA (2001). Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15, 50-65.
44. Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, Boss GR, and Green JE (1998). Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 17, 2403-2411.
45. Albertson DG, Collins C, McCormick F, and Gray JW (2003). Chromosome aberrations in solid tumors. Nat Genet 34, 369-376.
46. Vargo-Gogola T and Rosen JM (2007). Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7, 659-672.
47. Du Z and Li Y (2007). RCAS-TVA in the mammary gland: an in vivo oncogene screen and a high fidelity model for breast transformation? Cell Cycle 6, 823-826.
48. Du Z, Podsypanina K, Huang H, McGrath A, Toneff MJ, Bogoslovskaia E, Zhang X, Moraes RC, Fluck MM, Allred DC, et al. (2006). Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci USA 103, 17396-17401.
49. Talmadge JE, Wolman SR, and Fidler IJ (1982). Evidence for the clonal origin of spontaneous metastases. Science 217, 361-363.
50. Fidler IJ (2003). The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 3, 453-458.
51. Kerbel RS, Waghorne C, Korczak B, Lagarde A, and Breitman ML (1988). Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications. Cancer Surv 7, 597-629.
52. Moffett BF, Baban D, Bao L, and Tarin D (1992). Fate of clonal lineages during neoplasia and metastasis studied with an incorporated genetic marker. Cancer Res 52, 1737-1743.
53. Wicha MS, Liu S, and Dontu G (2006). Cancer stem cells: an old idea - a paradigm shift. Cancer Res 66, 1883-1890, discussion 1886-1895.